Sorrento Therapeutics Inc (SRNE)

[Brandywhitneylady]

Yes, it is unfortunate for all that believed the untruth put forth by our CEO. My commissions will be more than my shares are worth, so I guess I keep these until they drop to trips. GLTA.

[youssef]

https://finance.yahoo.com/news/sorrento-announces-full-enrollment-pivotal-130000089.html

[HeadsIwin]

I found it in the prospectuses.
Your right on that statement.
It's a ominous situation.
Damn that lawsuit.

[ezyE]

Link fo Bankruptcy
Now show link no more trails?

[Logon26]

All this trails are stopped, no money to push it - BK is very expensive / consultants with $1200 per hours and last month cost was over $600.000 only for consultants and lawyers

Page 7 - Assets only $752.900M - -$1,1B since February
https://www.sec.gov/Archives/edgar/data/850261/000110465923072951/tm2319181d1_ex99-1.htm

[ezyE]

Why don't you sell and go away
If that's the case

[Brandywhitneylady]

Our chapter 11 process has caused and may continue to cause our common stock and other securities to decrease in value, and may eventually render our common stock or other securities worthless.

Under the prospectus section. They even underlined it for you.

Really can’t find it? Wake up.

[Jesspro]

I did not find those words in your post “may render worthless”.

[Brandywhitneylady]

Read last nights news release. Why would I make that up? Like many here, I lost a bunch of money thanks to our fearless leader. But I am labeled a basher for stating the facts.


https://ih.advfn.com/stock-market/USOTC/sorrento-therapeutics-pk-SRNEQ/stock-news/91381982/current-report-filing-8-k:

[Brandywhitneylady]

Read the news release from last night.

[HeadsIwin]

Could you post the link for that statement, thanks.

[Brandywhitneylady]

From your hero, Dr J,

Our chapter 11 process has caused and may continue to cause our common stock and other securities to decrease in value, and may eventually render our common stock or other securities worthless.

Not sure what you don’t understand. Someone else please tell him.

[ezyE]

You don't say?
Been saying the same for awhile now ?
One day you might be right about something but this not the one

[Brandywhitneylady]

It won’t. Next will be dropping to pink sheets, class action lawsuits, then the great Dr. will take his million$$ and move on.

[dia76ca]

I don't know the exact timeline. SEMDEXA, SOCAZOLIMAB, OVYDSO and ABIVERTINIB all have very large partnering potential IMO! So I am very hopeful!

[ezyE]

Hi,you know when Sorrento out of bankruptcy?
Do you think our stock will be affected?

[CharlesNet]

https://cases.stretto.com/public/x228/12086/PLEADINGS/1208606122380000000116.pdf

[youssef]

https://finance.yahoo.com/news/scilex-holding-company-announces-sorrento-130300183.html

[dia76ca]

Jess...I am not sure. At one time they owned 25%. It is really just the big potential programs , that at present are wholly owned , that interest me. SEMDEXA, SOCAZOLIMAB, OVYDSO and ABIVERTINIB all have very large partnering potential IMO!

[Jesspro]

Dia76, does Sorrento still have a stake at Celiularity?

[dia76ca]

5 CATALYSTS ... any time now!
1. OVYDSO (Mpro)
2. SOCAZOLIMAB
3. ABIVERTINIB
4. SEMDEXA
5. PSS SETTLEMENT
OVYDSO, SOCAZOLIMAB and ABIVERTINIB news could come from China at any time. ROW partnerships for each should be worth multi-billions (upfront, milestones and royalties). SEMDEXA is also a multi-billion asset. PSS may want to settle out of court...or battle on and pay more in a court imposed settlement! All the best to all faithful longs!

[youssef]

https://finance.yahoo.com/news/sorrento-therapeutics-inc-announces-4-130000116.html

[AMA]

That is old news

[Andecker]

Well - good news here!
https://beststocks.com/ubs-group-ags-bold-investment-in-sorrento-therape/

Would like to see same info on fintel but this appears to have just been released today.

[dia76ca]

Nice. That is the TROP2 ADC listed in the Sorrento portfolio.

[youssef]

CHICAGO, June 05, 2023 (GLOBE NEWSWIRE) -- Shanghai Escugen Biotechnology Co., Ltd. (“Escugen”), a partner of Levena (Suzhou) Biopharma Co., Ltd. (“Levena”), a wholly owned subsidiary of Sorrento Therapeutics, Inc. (Sorrento), today released preliminary results from a first-in-human study of ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors at the 2023 Annual Meeting of ASCO, the American Society of Clinical Oncology, held June 2-6 in Chicago, IL. ESG401 is an innovative ADC developed by Escugen and Levena. Escugen and Levena Biopharma jointly own the domestic and international patents of this ADC and share global rights for the product. ESG401 is composed of a humanized anti-Trop2 IgG1 monoclonal antibody (mAb) conjugated to a topoisomerase I inhibitor SN38 via a proprietary stable covalent linker with a drug antibody ratio (DAR) of 8. ESG401 has potential differentiated advantages over its competitors in terms of safety, effectiveness and process robustness. Using an innovative, highly stable and cleavable linker, this ADC demonstrated that it releases very little free toxin during circulation, which may reduce off target toxicity in a series of preclinical studies. Additionally, premature release of the mAb may compete for binding sites with the ADC to reduce its efficacy. The ADC highly enriches in tumor tissues and rapidly endocytoses, thereby effectively killing tumor cells and inhibiting tumor growth.

In the Phase I study, adult ESG401 patients with locally advanced/metastatic solid tumors refractory to or relapsed from standard treatments with measurable disease (RECIST v1.1) were eligible. ESG401 was administered by IV infusion initially in an ascending dose safety study by designated dose and regimen until unacceptable toxicity or progressive disease and followed by expansion cohorts. The Bayesian Optimal Interval (BOIN) design was used to establish the maximum tolerated dose (MTD). As of February 3, 2023, 35 heavily pretreated patients with a median age of 53 years were treated with at least one dose of ESG401 during dose escalation, 2 to 20 mg/kg administered every 3 weeks (Regimen A), or 12 to 16 mg/kg on day 1, 8, and 15 in a 4-week cycle (Regimen B). Eighty percent of the patients had an ECOG status of 1. Sixty-three percent of the patients had received at least 3 lines of prior therapy and overall the number of lines of prior therapy was a median of 4 (range 2-10). A total of 94% of patients had visceral metastases (11% brain, 63% liver, 60% lung) at baseline. From the ASCO poster, patient demographics and baseline characteristics is shown below:

Sorrento Therapeutics, Inc.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bbc508be-c81f-4493-90e9-e6dc146cb70a

While one patient at 20 mg/kg reported a dose limiting toxicity (grade 4 neutropenia and grade 3 febrile neutropenia), the MTD was not reached. The most common treatment-related adverse events were leukopenia, neutropenia, anemia, fatigue and nausea or vomiting. The most common grade 3 events were leukopenia (29%) and neutropenia (31%) with no grade 3 thrombocytopenia, diarrhea, skin rash or oral mucositis. There was no evidence of interstitial lung disease. The frequency of TEAEs > 15% regardless of causality is shown below.

Sorrento Therapeutics, Inc.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/758ccb85-a5f2-4edb-a877-340b31789fe9

Of the 33 efficacy evaluable patients, 12 achieved partial responses and 4 achieved stable disease lasting at least 24 weeks. The dose of 16 mg/kg was identified as the therapeutically relevant dose. The overall response rate and disease control rate were 36% (4 of 11 patients) and 64% (7 of 11 patients), respectively, in patients with triple negative breast cancer, and 62% (8 of 13 patients) and 77% (10 of 13 patients), respectively, in patients who were HR+/HER2- breast cancer. Three patients have been on treatment for at least 12 months. These data demonstrate that ESG401 is well tolerated and demonstrates efficacy in heavily pretreated patients. Additional studies are ongoing with this innovative promising treatment. A waterfall plot of the data demonstrating the best % change in sum of longest dimension in target lesions from baseline is shown below for patients who received the therapeutic relevant dose (16 mg/kg).

Sorrento Therapeutics, Inc.A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d207ac66-1218-4605-8e27-dc66f6586667

About Escugen Biotechnology Co., Ltd.

Escugen Biotechnology Co., Ltd. is a clinical-stage biotechnology company committed to developing and commercializing innovative drugs for the treatment of cancer, autoimmune disease and other diseases with unmet medical needs. The company’s leading programs include ESG401, an anti-Trop2 antibody drug conjugate, currently in Phase Ib/II clinical trials in patients with locally advanced/metastatic solid tumors, and ESG206, an anti-BAFFR monoclonal antibody, currently in Phase I study in subjects with B-cell Lymphoid Malignancies.

About Sorrento Therapeutics, Inc.

Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease, and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as next-generation tyrosine kinase inhibitors ("TKIs"), fully human antibodies (“G-MAB™ library”), immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates (“ADCs”), and oncolytic virus (“Seprehvec™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including STI-1558 and COVI-MSC™, and diagnostic test solutions, including COVIMARK™.

Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a TRPV1 agonist, non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of postherpetic neuralgia (PHN). RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients. Positive final results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXA™, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. ZTlido® was approved by the FDA on February 28, 2018.

For more information visit www.sorrentotherapeutics.com

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding Sorrento’s products, technologies and prospects, the development of and prospects for ESG401 and ESG401’s potential advantage over any competitive products in terms of safety, effectiveness and process robustness. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's technologies and prospects, including, but not limited to risks related to safety and efficacy of ESG401and seeking regulatory approval for ESG401; clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks that prior test, study and trial results, including those for ESG401, may not be replicated in continuing or future studies and trials; risks of manufacturing and supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist Sorrento in the execution of its product candidates’ strategies; risks relating to the voluntary proceedings under Chapter 11 in the Bankruptcy Court (the "Chapter 11 Cases"), Sorrento's ability to continue operating in the ordinary course while the Chapter 11 Cases are pending, the timing and outcome of the Chapter 11 Cases, Sorrento's ability to obtain timely approval by the Bankruptcy Court of the motions filed in the Chapter 11 Cases, employee attrition and Sorrento's ability to retain senior management and other key personnel due to the distractions and uncertainties of the Chapter 11 Cases, Sorrento's ability to maintain relationships with suppliers, customers, employees and other third parties and regulatory authorities as a result of the Chapter 11 Cases, the Bankruptcy Court's rulings in the Chapter 11 Cases, the length of time that Sorrento will operate under Chapter 11 protection and the continued availability to Sorrento of operating capital during the pendency of the Chapter 11 Cases, risks associated with any third party motions in the Chapter 11 Cases, increased administrative and legal costs related to the chapter 11 process, exposure to potential litigation and inherent risks involved in a bankruptcy process, the potential adverse effects of the Chapter 11 Cases on Sorrento's liquidity or results of operations, or Sorrento's ability to timely file its periodic reports or meet periodic reporting requirements with the SEC; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

[youssef]

https://finance.yahoo.com/news/scilex-holding-company-enters-master-191600455.html

[dia76ca]

SORRENTO COVID,IMMUNOTHERAPY, PAIN AND LYMPHATIC DELIVERY PROGRAMS
COVID-19 PROGRAMS
Key Programs (Indication) Phase
COVISTIX™ (diagnostic) FDA EUA
COVIMARK™ (diagnostic) FDA EUA
VIREX (diagnostic) PH III
FUJOVEE™ (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
OVYDSO (Olgotrelvir) Ph II
Omicron mRNA Vaccine Preclinical

IMMUNOTHERAPY PROGRAMS
Key Programs (Indication) Phase
FUJOVEE™ (Abivertinib) Ph III
FUJOVEE™ (Abivertinib) Ph II
FUJOVEE™ (Abivertinib) Preclinical
PD-L1 (Socazolimab)* Ph III
PD-L1 (STI-3031)** Ph III
CD47 (Solid Tumors) Ph I
CD38 DAR-T (Multiple Myeloma) Ph I
CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, and esophageal) Ph I
TROP2 ADC* (Solid Tumors) Ph I
Seprehvec™ oncolytic virus (Solid Tumors; CNS Tumors) PH I
BCMA ADC (Liquid Tumors) Preclinical
Bevacizumab-ADNAB™ (Endometrial Cancer) Ph I
Bevacizumab-ADNAB™ (Ovarian Cancer) Ph I
Rituximab-ADNAB™ (B-cell Lymphomas) Ph I
Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma

PAIN PROGRAMS
Key Programs (Indication) Phase
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) FDA Approval
Gloperba® 1.8% Treatment of Gout (Oral) FDA Approval
SEMDEXA (SP-102) Ph III
SP-103 (Lidocaine Topical System 5.4%) Ph II
SP-104 (Delayed Burst Low Dose Naltrexone) Preclinical
RTX (resiniferatoxin) Epidural injection Ph II
RTX (resiniferatoxin) Intra-articular route Ph II

LYMPHATIC DELIVERY PROGRAM
Key Programs (Indication) Phase
Sofusa® anti-TNF (Autoimmune RA) Ph I
Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I
Sofusa® anti-CTLA-4 (Melanoma) Ph I

[dia76ca]

Big Pharma need to refill their pipelines!
Astellas buys Iveric Bio for about $5.9 billion for opthalmology treatments.

Takeda bought Nimbus Therapeutics psoriasis unit for $6 billion in December.

Sorrento has at least 5 phase 3 drugs to spin off for multi-billions.

Abivertinib, 2 PD-L1's, Semdexa and Ovydso.

JUST ONE SALE OR PARTNERSHIP IS NEEDED!

[CharlesNet]

Maybe this will help ??

[youssef]

https://finance.yahoo.com/news/scilex-holding-company-added-preliminary-130000133.html

[HeadsIwin]

Looks like we have a nice breeze in the sails, hope the prevailing winds stay strong thur Friday

[youssef]

https://finance.yahoo.com/news/sorrento-therapeutics-inc-bankruptcy-court-190000312.html

[Brandywhitneylady]

Oh, what a surprise, another Friday after hours release…..3 million more shares to dump? The last round of massive dilution before the reverse split. Let’s burn those shorts Doc, oh wait it was a planned bankruptcy filing, I forgot.
How’s that pipeline doing? This will be a nickel by end of May, so load up!
Oh, wait Moderna was going to buy us out, so it may be a dime….

[Brandywhitneylady]

Or the SS Minnow.

[HeadsIwin]

If JI was our boat Captain we 'd have a mutiny.
He'd be flogged over a barrel.
He probably take it as reforcement of doing good. I'm getting a feeling I'm on the Titanic.

[runcaly]

This is the great US-Market, its normal ?
05/10/2023 7:22:39 EDTI 1 x 4.888
05/10/2023 7:22:23 EDTI 1 x 4.892
05/10/2023 7:22:20 EDTI 2 x 4.891
05/10/2023 7:21:52 EDTI 3 x 4.912
05/10/2023 7:21:47 EDTI 5 x 4.925
05/10/2023 7:19:29 EDTI 1 x 5.091
05/10/2023 7:19:17 EDTI 2 x 5.10

[ezyE]

I can float until dry land

[Brandywhitneylady]

7. The stock is under a quarter.

The ship is sinking, the great Dr. is drilling holes in the bottom to let the water out.

[Brandywhitneylady]

Adios.

[dia76ca]

I've been away on a 3 week cruise so I don't pretend to know much about what has gone on recently. So please correct me if my assumptions are wildly incorrect!
ASSUMPTIONS
Sorrento has about 600 million shares out.
Insiders hold about 1%
Institutions hold about 30%
Sorrento holds about 40-50% of Scilex
CATALYSTS(drugs other companies may want to partner or acquire)
1. SEMDEXA ph.3 complete USA
2. OVYDSO ph.3 CHINA
3. ABIVERTINIB ph.3 NDA CHINA
4. SOCAZOLIMAB ph.3 NDA CHINA
5. PSS settlement anytime pretrial (Following DOMINION/FOX settlement model)
6. Lymphatic drug delivery technology
Any of these partnerships or settlements could happen at any time!

[HeadsIwin]

The question BUY or BYE ?

[Brandywhitneylady]

If I sell my SRNE stock, I may be able to buy a queen size.
The Ji empire is crumbling, give Scilex another couple weeks and it will be the third stock he has drove under $1.00. The class actions are coming Doc.

[ezyE]

You can buy a downs pillow

[Brandywhitneylady]

We need some fluff guys, how about the “pipeline”? What about Covi-Stix? Brazil testing, China phase 7 or whatever they are at? Winning the lawsuit? The cure for cancer? Cmon Doc, you must have something! The multi million dollar campus is gone, where is the Great Ji working at, some tropical island right?

[Logon26]

„ then the PPS would go lower and they would not be able to raise the amount of money that the company wants to with the least amount of share issuance.“
Check the SP since 19th April, down from 14.50 to 6.79

[Here Today]

This only has to do with the shares that were given to Shareholders of SRNEQ as a dividend. Reason they are doing this through the bankruptcy legal system is to put all the Brokerages and MM’s on notice that not only cannot these shares be traded but also Cannot be Lended to start or cover a Short position.

SCLX just filed to sell some shares in the open market and if all the shares that were given as a dividend were free floating, then the PPS would go lower and they would not be able to raise the amount of money that the company wants to with the least amount of share issuance.

[Logon26]

Delay restriction for Silex divi shares to 1. September 2023 …maybe only to recall all SCLX divi shares from shareholders, we will see. Bankruptcy is a dirty campaign against shareholders, mark my words!

[Brandywhitneylady]

Oh wait, now we can’t dump Scilex for another anther 6 months…

[Brandywhitneylady]

Yes. And I see the great Dr. is doing us well on our “dividend” stock, Scilex, down 50% in the last week. Maybe when we are able to dump this one, it will also be at $ .35. Nice work Doc.